Company: SMNR
Filing Date: 2025-07-02
Form Type: S-4/A
Source: 0001193125-25-154936
Chunk: 861

Company: Semnur Pharmaceuticals, Inc.
Filing Date: 2025-07-02
Form: S-4/A
Chunk 861
---
Scilex Bio”), to develop and commercialize a next-generation reversible MAO-B Inhibitor, a novel inhibitor of aberrant GABA production in reactive astrocytes for the treatment of obesity and neurodegenerative diseases including Alzheimer’s disease. Scilex contributed 5.0 million shares of Semnur Common Stock owned by Scilex to Scilex Bio in exchange for a 60% ownership interest in Scilex Bio and IPMC Company contributed certain assets to Scilex Bio in exchange for a 40% ownership interest in Scilex Bio. F-97

#### Annex A-1

### AGREEMENT AND PLAN OF MERGER

#### dated as of August 30, 2024

#### by and among

#### Denali Capital Acquisition Corp.,

#### Denali Merger Sub Inc.,

#### and

#### Semnur Pharmaceuticals, Inc.
TABLE OF CONTENTS

|                                                         |     |                                                                      |     | Page   |
| ARTICLE I DEFINITIONS                                   |     |                                                                      |     | A-1-2  |
| ARTICLE II DOMESTICATION                                |     |                                                                      |     | A-1-13 |
| 2.1                                                     |     | Domestication                                                        |     | A-1-13 |
| 2.2                                                     |     | Plan of Domestication                                                |     | A-1-13 |
| ARTICLE III MERGER                                      |     |                                                                      |     | A-1-13 |
| 3.1                                                     |     | Merger                                                               |     | A-1-13 |
| 3.2                                                     |     | Closing; Effective Time                                              |     | A-1-14 |
| 3.3                                                     |     | Directors and Officers                                               |     | A-1-14 |
| 3.4                                                     |     | Effect of the Merger                                                 |     | A-1-14 |
| 3.5                                                     |     | Certificate of Incorporation and Bylaws of the Surviving Corporation |     | A-1-14 |
| 3.6                                                     |     | Unit Separation                                                      |     | A-1-15 |
| 3.7                                                     |     | Section 368 Reorganization                                           |     | A-1-15 |
| 3.8                                                     |     | Withholding Rights                                                   |     | A-1-15 |
| ARTICLE IV CONSIDERATION                                |     |                                                                      |     | A-1-15 |
|